Clinical trials
Cancer (With or Without Metastasis) clinical trials
Below are recruiting cancer (with or without metastasis) clinical trials, each written for real people, not researchers. We’re tracking 13,052 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
Duarte, CaliforniaAges 18–99 - NCT07589517RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Colorectal Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT07589413Recruiting
Blood markers and fluid absorption during bladder cancer surgery
This study looks at how fluid absorbed during bladder cancer removal surgery affects cell-free DNA (tiny pieces of cancer DNA) in your blood. Researchers want to understand if these blood markers can help predict surgery outcomes and guide treatment decisions.
Lanzhou, GansuAges 18 years+ - NCT07594522RecruitingPhase 1/Phase 2
Ivonescimab with Radiation for Early Lung Cancer
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
Basking Ridge, New JerseyAges 18 years+ - NCT07594925RecruitingPhase 2
Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
TianjinAges 18–75 - NCT07591701Recruiting
Understanding prostate cancer trial opportunities at LBJ Hospital
This study helps doctors learn how to invite more diverse patients into prostate cancer clinical trials at LBJ Hospital. You may qualify if you have prostate cancer, receive care at LBJ, and are eligible for an open trial there.
Houston, TexasAges 18 years+ - NCT07594067RecruitingPhase 1
TCR T cells for KRAS-mutated cancers
This trial tests a new type of immune cell therapy (TCR T cells) designed to target a specific KRAS mutation (G12V) in certain advanced cancers. It may be an option for people with pancreatic, bile duct, colorectal, or lung cancer who have already tried standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04590560Recruiting
Best timing for breast screening in women ages 45–49 and 70–74
This study looks at the best time interval for breast cancer screening (mammograms) for women in two age groups. The goal is to reduce missed cancers while avoiding unnecessary tests.
Meldola (FC), FCAges 45–49 - NCT07578116RecruitingPhase 3
Adding surgery and radiation for her2-positive breast cancer with a few spread spots
This trial tests whether adding surgery and radiation to the usual HER2-targeted treatment helps people with breast cancer that has spread to a few spots. You must have HER2-positive cancer that is newly spread, and you must be able to receive radiation to all tumor sites.
Jonesboro, ArkansasAges 18 years+ - NCT07581834RecruitingPhase 2
Dalpiciclib plus hormone therapy for early hormone-positive breast cancer
This study tests whether adding a new drug called dalpiciclib to standard hormone therapy improves outcomes for women with early-stage breast cancer that is hormone-receptor positive. The goal is to see if this combination is more effective and safe than hormone therapy alone.
Fuzhou, FujianAges 18 years+ - NCT07582887Recruiting
Genetic Testing to Predict Side Effects from Breast Cancer Antibody Drugs
This study examines how genetic differences affect how your body handles three newer breast cancer medications (Sacituzumab Govitecan, Trastuzumab Deruxtecan, or Datopotamab Deruxtecan). A blood test will check your UGT1A1 gene to help doctors predict which side effects you might experience and adjust your treatment accordingly.
Granada, GranadaAges 18 years+ - NCT07584161Recruiting
Radiation therapy comparison after cervical or endometrial cancer surgery
This trial compares two types of radiation therapy (a newer technique called MH-ART versus a standard technique called CF-IMRT) given after surgery for cervical or endometrial cancer. The goal is to see which approach works better and causes fewer side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT07583160Enrolling by invitationPhase 1
YS247 Vaccine for Advanced Prostate Cancer
This trial tests a personalized cancer vaccine (YS247) designed to train your immune system to recognize and fight your prostate cancer. It may help slow or stop cancer growth in men whose cancer has spread and stopped responding to standard hormone treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07581080Recruiting
Biofield therapy to ease fatigue from cancer immunotherapy
This study tests whether Reiki—a hands-on healing practice—can help reduce severe tiredness in cancer patients receiving immunotherapy drugs. If it works, it could offer patients another way to manage fatigue alongside their cancer treatment.
Irvine, CaliforniaAges 18 years+ - NCT07579195RecruitingPhase 1/Phase 2
Consolidation therapy after EV + pembro in bladder cancer
This trial tests whether adding radiation therapy or bladder-removal surgery (consolidation) after EV + pembrolizumab helps control muscle-invasive bladder cancer that has spread. It is for people whose cancer responded to the initial drug combination.
Seattle, WashingtonAges 18 years+ - NCT07579221RecruitingPhase 1/Phase 2
Navlimetostat and Pumitamig for Advanced Lung Cancer
This study tests a combination of two experimental drugs (navlimetostat and pumitamig) for advanced non-small cell lung cancer in patients whose tumors have a specific genetic change called MTAP loss. The drugs are designed to attack cancer cells in a new way and may help patients whose cancer has stopped responding to previous treatments.
Houston, TexasAges 18 years+ - NCT06019455Recruiting
How patients participate in lung and esophageal cancer care
This study looks at how much patients with lung or esophageal cancer get involved in decisions about their care when they receive chemotherapy and radiation together. It aims to learn what helps or challenges patients in taking an active role.
GuangzhouAges 18–75 - NCT06728852RecruitingPhase 2
Vorolanib for advanced lung cancer after other treatments
This trial tests a targeted therapy pill called Vorolanib for people with advanced non-small cell lung cancer who have already tried at least two other treatments. It aims to see if the drug can help shrink or control the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06728865RecruitingPhase 2
Furmonertinib plus Avastin for EGFR+ lung cancer with brain mets
This trial tests a combination of two targeted drugs (Furmonertinib and Avastin) as the very first treatment for people with a specific type of lung cancer (EGFR-mutant non-small cell) that has spread to the brain. The goal is to see how well it works and how safe it is.
Guangzhou, GuangdongAges 15–75 - NCT06729684Recruiting
Digital health program for breast cancer side effects
This study is testing a personalized digital health program to help breast cancer survivors manage side effects. It uses a smartphone app to track symptoms and offer support.
Seoul, Republic of KoreaAges 18–65 - NCT06430983Recruiting
Relearning liver cancer: a study of recurrent cases
This trial studies patients with liver cancer, including both the common type (hepatocellular carcinoma) and other types. It aims to understand the cancer better by collecting blood samples and medical information.
Nanjing, JiangsuAges 18–75 - NCT04278287RecruitingPhase 1/Phase 2
Chemoradiation study for unresectable esophageal cancer
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
Anyang, HenanAges 18–75 - NCT06100718Recruiting
Detecting new cancer after a stroke in at-risk patients
This study looks for hidden cancers in people who have had a stroke and have high levels of a blood marker called D-dimer. It aims to see if a full cancer screening one year later can find new cancers that might have been missed.
Lausanne, Canton of VaudAges 18 years+ - NCT07567846RecruitingPhase 1/Phase 2
GDC-1261 Safety and Activity in Advanced Prostate Cancer
This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.
Scottsdale, ArizonaAges 18 years+
Hear when a new Cancer (With or Without Metastasis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer (with or without metastasis)?
- Yes. Clin2 currently lists 13,052 recruiting cancer (with or without metastasis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer (with or without metastasis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer (with or without metastasis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Liver Metastasis Colon Cancer
- Gastric Cancer, Gastroesophageal Junction Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Colorectal Cancer Liver Metastasis
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Leptomeningeal Metastasis of Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.